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Methamphetamine (MA) is a highly addictive psychomotor stimulant, with life-time
prevalence rates of abuse ranging from 5–10% world-wide. Yet, a paucity of research
exists regarding MA addiction vulnerability/resiliency and neurobiological mediators of the
transition to addiction that might occur upon repeated low-dose MA exposure, more
characteristic of early drug use. As stimulant-elicited neuroplasticity within dopamine
neurons innervating the nucleus accumbens (NAC) and prefrontal cortex (PFC) is theorized
as central for addiction-related behavioral anomalies, we used a multi-disciplinary research
approach in mice to examine the interactions between sub-toxic MA dosing, motivation
for MA and mesocorticolimbic monoamines. Biochemical studies of C57BL/6J (B6)
mice revealed short- (1 day), as well as longer-term (21 days), changes in extracellular
dopamine, DAT and/or D2 receptors during withdrawal from 10, once daily, 2mg/kg MA
injections. Follow-up biochemical studies conducted in mice selectively bred for high
vs. low MA drinking (respectively, MAHDR vs. MALDR mice), provided novel support
for anomalies in mesocorticolimbic dopamine as a correlate of genetic vulnerability to
high MA intake. Finally, neuropharmacological targeting of NAC dopamine in MA-treated
B6 mice demonstrated a bi-directional regulation of MA-induced place-conditioning.
These results extend extant literature for MA neurotoxicity by demonstrating that even
subchronic exposure to relatively lowMA doses are sufficient to elicit relatively long-lasting
changes in mesocorticolimbic dopamine and that drug-induced or idiopathic anomalies in
mesocorticolimbic dopamine may underpin vulnerability/resiliency to MA addiction.
Keywords: methamphetamine, sensitization, nucleus accumbens, dopamine, prefrontal cortex, serotonin,
addiction vulnerability
INTRODUCTION
Methamphetamine (MA) is a potent, highly addictive,
amphetamine derivative with intense psychomotor-activating
properties. MA abuse is linked to pronounced cognitive, behav-
ioral and emotional deficits, with a high relapse potential,
constituting a major public health concern (e.g., Rusyniak, 2011;
Dean et al., 2013). While MA ranks second highest as the most
commonly abused illicit drug in the world (United Nations
Office on Drugs and Crime, 2011), neurobiological research
concerning genetic vulnerability to MA abuse/addiction and the
impact of early MA experience on the brain to the development
of early-stage addiction is limited.
MA is a substrate for plasma membrane monoamine trans-
porters, including the dopamine (DA) transporter (DAT), as well
as for the vesicular monoamine transporter, and is reported to
also inhibit monoamine oxidase (e.g., Fleckenstein et al., 2007;
Chen et al., 2009). Through these mechanisms, MA profoundly
increases DA within forebrain terminals, notably nucleus accum-
bens (NAC), dorsal striatum and prefrontal cortex (PFC) (e.g.,
Sulzer et al., 2005). As such, the majority of neurobiological
research pertaining to MA addiction has focused primarily on
MA-forebrain DA interactions (e.g., McCann and Ricaurte, 2004;
Yamamoto and Bankson, 2005; Espana and Jones, 2013). The
majority of extant pre-clinical data has been derived using very
high-dose MA treatment regimens (10–100mg/kg acutely or
binge administration of 4–10mg/kg given multiple times within
a day) that elicit neurotoxicity within dorsal striatal regions (for
recent reviews on the subject: Kuhn et al., 2011; Carvalho et al.,
2012; Ares-Santos et al., 2013; Halpin et al., 2014). While we
have gained tremendous molecular and cellular insight into how
high-dose MA experience produces forebrain damage of rele-
vance to late-stage addiction, to the best of our knowledge, less
than 15 reports exist pertaining to the interactions between fore-
brain dopamine systems and low-dose, subchronic exposure to
MA (e.g., Zhang et al., 2001; Broom and Yamamoto, 2005; Ago
et al., 2006, 2007, 2012; Segal and Kuczenski, 2006; Fukakusa
et al., 2008; Schwendt et al., 2009; Lominac et al., 2012; Lac´an
et al., 2013; Le Cozannet et al., 2013). Also, whereas it is gen-
erally held that repeated MA exposure elicits a sensitization of
forebrain dopamine release that contributes to the development
of behavioral sensitization and/or underpins this drug’s positive-
reinforcing or rewarding properties (e.g., Ujike et al., 1989; Yang
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et al., 2008a,b), discrepancies exist regarding the relative roles
played by DA within different forebrain terminal regions, most
notably the NAC vs. mPFC (see Ago et al., 2006, 2007, 2012).
Moreover, in comparison to the extant data for cocaine and
d-amphetamine (c.f., Robinson and Becker, 1986; Vanderschuren
and Kalivas, 2000) and for high-dose MA exposure (c.f., Carvalho
et al., 2012), we know relatively little regarding how MA expo-
sure early during the use of the drug impacts the brain. As such
an understanding has relevance to the transition from MA use
to abuse/addiction, the first study presented here examined the
effects short and longer-termwithdrawal from repeatedMA upon
basal extracellular DA (DAEC) content, DAT and D2/3 recep-
tor (D2/3R) expression, as well as MA-induced DA sensitization,
experimenter-administered, MA injections after short-term and
longer-term withdrawal in the NAC and PFC. Prior studies have
indicated that the effects of contingent vs. non-contingent intra-
venous MA upon striatal indices of DAEC do not depend highly
upon the behavioral contingency of MA delivery and are quali-
tatively similar (Lominac et al., 2012; Lac´an et al., 2013). Thus,
we employed a repeated, experimenter-administered injection
regimen for this study as this route of MA administration is
technically facile in mice.
Another major question pertaining to the neurobiology of
MA addiction is why only certain individuals come to repeat-
edly abuse MA in the first place? This question has also received
very little direct experimental attention, until recently (Ikeda
et al., 2007; Morita et al., 2008; Phillips et al., 2008; Uhl et al.,
2008; Wheeler et al., 2009; Shabani et al., 2011, 2012a,b). In
humans, moderate doses of amphetamine-type stimulants (e.g.,
0.1–0.4mg/kg) elicit euphoria and behavioral activation, which
are typically considered appetitive/reinforcing; higher, subtoxic,
MA doses (e.g., 1.0–4.0mg/kg) can induce anxiety and elicit
psychophysiological symptoms, which can be perceived as aver-
sive (c.f., Cruickshank and Dyer, 2009). As for other drugs
of abuse (e.g., Schuckit et al., 1997; Fergusson et al., 2003;
Petrakis et al., 2004), individual differences in sensitivity to MA’s
rewarding vs. aversive effects might influence addiction risk.
Thus, experimental attention regarding the neurobiological sub-
strates of MA addiction vulnerability is critical to understand
MA addiction etiology, identify potential biomarkers for MA
addiction vulnerability/resiliency and develop treatment strate-
gies for early intervention in the disease process. The advent
of mice selectively bred to drink higher vs. lower amounts
of MA (Methamphetamine High Drinking or MAHDR and
Methamphetamine Low Drinking or MALDR) that not only
differ in their MA intake and preference under free-access 2-
bottle-choice procedures (Wheeler et al., 2009), but also exhibit
divergent phenotypes under operant and place-conditioning pro-
cedures (Shabani et al., 2011, 2012a,b) provide the opportunity to
identify biochemical correlates of high vs. low genetic risk for MA
addiction-related behaviors. Thus, we also determined whether
or not dopamine anomalies were correlates of genetic vulnerabil-
ity/resiliency toMA addiction-related behavior and assayed, using
neuropharmacological approaches, the role for forebrain DA in
MA preference in inbred mice. As the results of an earlier study
of MAH/LDR mice suggested anomalies in serotonin (5HT) as a
biochemical correlate of high MA intake (Wheeler et al., 2009),
we also examined for line differences in indices of forebrain 5HT
function.
MATERIALS AND METHODS
SUBJECTS
Most studies employed adult, male (8 weeks old) C57BL/6J (B6)
mice (Jackson Laboratories, Sacramento, CA). For studies of the
biochemical correlates of genetic vulnerability/resiliency for MA
intake, adult female MA High Drinking and MA Low Drinking
(MAH/LDR)mice on amixed C57BL/6J and DBA2/J background
were generated at the Portland VA Medical Center (see Wheeler
et al., 2009) and shipped to UCSB Santa Barbara, where they were
acclimatized for a minimum of 6 weeks. Mice were housed in
groups under a regular 12-h light:dark cycle (lights off at 19:00 h),
with food and water available ad libitum. All experimental pro-
tocols were consistent with the guidelines put forth by the NIH
(NIH Publication No. 80–23, revised 1996) and were approved
by the Institutional Animal Care and Use Committees of the
University of California Santa Barbara and Oregon Health and
Science University.
STEREOTAXIC SURGERY
The surgical procedures for implanting stainless steel guide can-
nulae (10mm, 20 gauge, Small Parts; Roanoke, VA) above the
mPFC and NAC of mice were identical to those described recently
(see Ary et al., 2013). For studies involving in vivo microdialysis
or microinjection procedures (see below), mice were anesthetized
using 1.5–2% isoflurane with 4% oxygen as a carrier gas. Mice
were mounted in a stereotaxic device with tooth and ear bars
adapted for mice. The animal’s skull was exposed, leveled, and
holes were drilled based on coordinates from Bregma for the
mPFC (AP: +1.8mm; ML: ± 0.5mm; DV: −1.0mm) or NAC
(AP: +1.3mm, ML: ±1mm, DV: −2.3mm), according to the
mouse brain atlas of Paxinos and Franklin (2007). The guide
cannulae were lowered bilaterally such that the tips of the can-
nulae were 3mm above the mPFC or border region of the shell
and core subregions of the NAC. The skull was then prepared
for polymer resin application, the 2 guide cannulae occluded and
post-operative care was conducted as described previously (e.g.,
Ary et al., 2013). Probe placements within the mPFC and NAC
were verified prior to any statistical analyses using microscopic
analysis of Nissl-stained sections. Only those mice exhibiting cor-
rect placement within the boundaries of the mPFC or NAC were
included in the statistical analyses of the data (see e.g., Figure 1).
MA TREATMENT AND EXPERIMENTAL DESIGN
Studies of B6 mice
Following either a minimum of 5 days recovery from surgery or
following acclimation to the vivarium, B6 mice were randomly
assigned to receive either repeated intraperitoneal injections of
2mg/kg MA (Sigma Aldrich; St Louis, MO) or an equivalent
volume of 0.09% saline (SAL; vol = 0.01ml/kg). MA/SAL injec-
tions were administered once daily, for 10 consecutive days, as
this regimen is reported to alter NAC DA in rats (Broom and
Yamamoto, 2005). In vivo microdialysis procedures or sacrifice
for immunoblotting were conducted at either 1 or 21 days with-
drawal in B6 mice. Whenever possible (see below), the B6 mice
Frontiers in Systems Neuroscience www.frontiersin.org May 2014 | Volume 8 | Article 70 | 2
Lominac et al. Methamphetamine, motivation, and mesocorticolimbic monoamines
FIGURE 1 | Summary of the dopamine response to an i.p. challenge
injection of 2mg/kg methamphetamine (MA), administered at either 1
day (left) or 21 days (right) withdrawal (WD), exhibited by B6 mice with a
10-day history of repeated MA (2mg/kg) or saline (SAL). When measured
in either the nucleus accumbens (NAC; A,B) or the medial prefrontal cortex
(mPFC; C,D). The data are expressed as the percent change from the average
baseline level and represent the means ± s.e.m’s of the number of animals
indicated in parentheses in each panel. ∗p < 0.05 vs. SAL (i.e., sensitization).
underwent 2 identical microdialysis sessions; the first session was
conducted at 1 day withdrawal and the second session was con-
ducted at 21 days withdrawal to d and separate groups of animals
were used to assay for MA-induced changes in basal DA con-
tent, for basal D2R function, for basal DAT function and for
MA-stimulated release (n = 10–12 at the outset of each assay),
as described below.
Studies of MAH/LDR mice
Due to the relatively limited number of animals available, the
MAH/LDR mice were randomly assigned to in vivo microdialy-
sis or immunoblotting studies. Mice in the in vivo microdialysis
studies were assayed in 2 distinct microdialysis sessions, sepa-
rated by 2–3 days, and for these sessions, microdialysis probes
were lowered into guide cannulae implanted on opposite hemi-
spheres. In one session, we assayed for basal DA or 5HT content
using no net-flux procedures (counterbalanced across animals
within genotype). In the second session, mice were assayed for
the basal content of the other neurotransmitter. Another group
of animals only underwent 1 microdialysis session in which we
assayed for the effects of an acute injection of MA (2mg/kg) upon
monoamine levels and thus, a microdialysis probe was inserted
unilaterally, with the hemisphere counter-balanced across ani-
mals. For the immunoblotting studies, half of the MAH/LDR
mice were administered an acute injection of 2mg/kg MA to
examine for potential drug effects upon protein expression; the
remaining half were administered an acute injection of saline for
comparison. At 3 h post-injection, tissue was collected for pro-
cessing by immunoblotting to be consistent with the experimental
design of an earlier report examining for genotype differences in
mRNA expression (Wheeler et al., 2009).
In vivo microdialysis
Microdialysis was conducted in repeated MA/SAL-treated B6
mice at 1 and 21 days withdrawal or in MAH/LDR mice using
procedures very similar to those described recently in Ary et al.
(2013). For each microdialysis session, a probe was inserted uni-
laterally into the mPFC or the NAC, counterbalancing across
hemispheres between groups. The animals were then connected
a liquid swivel (Instech; Plymouth Meeting, PA) and perfused
(2μl/min) with microdialysis buffer (NaCl, 147mM, CaCl2,
1.2mM, KCl, 2.7mM, MgCl2, 1.2mM, Na2HPO4, 0.5mM;
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adjusted to pH = 7.4). Following a 3-h equilibration period,
dialysate collection began and occurred in 20-min intervals
into vials containing 10μl of preservative (4.76mM citric acid,
150mM NaH2PO4, 50μM EDTA, 3mM sodium dodecyl sul-
fate, 10% methanol (v/v), 15% acetonitrile (v/v), pH = 5.6). The
duration of testing ranged from 3–4 h, depending upon the exper-
iment (see below). Upon completion of a session, animals were
lightly restrained for probe removal and the dummy cannula rein-
serted. It should be noted that while each in vivo microdialysis
study commenced with n = 10–12 mice (depending upon the
study), we were not always able to obtain data from all animals
from the first in vivo microdialysis sessions due to a loss of probe
patency during sampling, misplaced guide cannula or HPLCmal-
function. The final sample sizes indicated in the Results below
reflect the final number of animals for which we successfully
obtained all samples for the session and for which the probes were
localized within the intended region. While not always possible
for additional technical reasons (e.g., dislodged cranial implant;
clogged cannulae; n = 2–4/replicate), a second microdialysis ses-
sion was conducted by inserting a probe into the guide cannula
implanted in the opposite hemisphere. This 2nd session occurred
either at 21 days withdrawal from repeated MA/SAL (B6 mice) or
a minimum of 3 days following the 1st session (MAH/LDRmice).
Thus, of the total number of mice at the outset of each study,
we successfully obtained data from both microdialysis sessions
for approximately 70% of the subjects tested and this percentage
ranged depending upon the study and the number of technical
issues that were encountered at the time of sample collection and
HPLC analyses.
All microdialysis studies commenced with a 1-h baseline sam-
pling period. To examine the effects of MAH/LDR genotype and
of repeated MA treatment on MA-stimulated dopamine release,
mice were injected with 2mg/kg MA and dialysate was collected
for an additional 3 h. For the study of repeated MA effects or
MAH/LDR genotype differences in basal extracellular dopamine
content, we employed quantitative in vivo microdialysis proce-
dures, in which increasing concentrations of DA (Sigma Aldrich)
were diluted in aCSF to concentrations encapsulating biologi-
cal levels (0, 2.5, 5, and 10 nM; e.g., Sam and Justice, 1996) and
perfused in ascending order for 1 h each. The basal extracel-
lular serotonin (5HT) content was also assayed in MAH/LDR
mice (0–10 nM; Sigma Alrich). Linear regression analyses were
employed to calculate the point of no net-flux (y = 0) and the
slope of the plot (i.e., the extraction fraction or Ed; an index
of neurotransmitter release and reuptake; e.g., Sam and Justice,
1996), which were analyzed using between-subjects ANOVAs. To
relate the MA-induced changes in extracellular dopamine (DAEC)
observed in B6 mice to drug effects on DAT and D2 autorecep-
tor function, we assayed the effects of reverse dialyzing the DAT
inhibitor GBR-12909 (0, 1, 10, and 100μM; Pierce and Kalivas,
1997) or the D2-like DA receptor antagonist (±) sulpiride (0, 50,
100μM; Engleman et al., 2004). In the studies of D2-like recep-
tor function, sulpiride was infused in lieu of a D2R agonist, as the
results of published studies and unpublished pilot studies in our
laboratory have failed to reliably detect changes in DAEC using
this approach (e.g., Galloway et al., 1986; Santiago et al., 1993; Liu
and Steketee, 2011), while the local infusion of D2R antagonists
more reliably alter DAEC (Engleman et al., 2004; present study).
All compounds were dissolved in microdialysis buffer, although
sulpiride required initial dissolution in 50μL of acetic acid and
the final pH ranged from 6.9–7.3, depending upon the replicate.
Each drug concentration was infused for 1 h, akin to the quantita-
tive microdialysis procedures above. Given the known differences
in basal DA levels confirmed by no net-flux microdialysis and the
susceptibility of these procedures to differences in probe recovery
(Westerink and Cremers, 2007), all data for MA-induced neu-
rotransmitter release and for reverse dialysis experiments were
expressed as a percent change from baseline. The microdialy-
sis data were analyzed using ANOVAs with repeated measures
across the Time or Dose factors and interactions deconstructed
for simple effect analyses, followed by post-hoc comparisons using
t-tests.
HPLC Analysis
Dopamine and serotonin in 27μl dialysate was measured using
high pressure liquid chromatography (HPLC) with electrochem-
ical detection using an ESA Coularray HPLC system (ESA Inc.;
Bedford, MA). For this, MD-TM mobile phase was employed
(Thermo Dionex), and monoamine neurotransmitters were sep-
arated using an MD-150 × 3.2 column (C18, 150mm × 3.2mm
I.D.; Thermo Dionex). An ESA 5014B analytical cell with
two electrodes was used for the electrochemical detection of
monoamines—the reduction analytical electrode (E1,−150mV),
and an oxidation analytical electrode (E2, +220mV). Dopamine
and serotonin content in each sample was analyzed by peak height
and compared to external standard curves (one for each neu-
rotransmitter) for quantification (e.g., Szumlinski et al., 2007).
Unfortunately, our HPLC conditions did not permit reliable
detection of norepinephrine in the dialysate.
IMMUNOBLOTTING
Immunoblotting was conducted on whole-cell tissue homogenate
collected from the mPFC, NAC shell and NAC core of B6 mice
at either 1 or 21 days withdrawal from repeated MA treatment
(10 × 2mg/kg) or of MAH/LDR mice 3 h following an acute
injection of SAL or 2mg/kg MA (to be consistent with the exper-
imental design of a prior assay of mRNA levels; Wheeler et al.,
2009). To relate MA’s effects upon indices of DAEC in B6 and
MAH/LDR mice, we examined for the total protein expression
of DAT and D2 dopamine receptors (D2Rs), the latter of which
serves as an autoreceptor regulating DAEC. We also related MA’s
effect upon indices of 5HTEC in MAH/LDR mice to the total
protein expression of SERT and 5HT1B receptors (5HT1BRs),
the latter of which serves as an autoreceptor on 5HT termi-
nals. The general procedures used to dissect and homogenize
tissue, as well as to separate, transfer and visualize proteins were
described recently (Ary et al., 2013). The PFC, NAC shell and
NAC core were excised over ice and frozen at −80◦C until assay.
Tissue was homogenized with a PTFE hand-held tissue grinder
in homogenization medium consisting of 0.32M sucrose, 2mM
EDTA, 1% sodium dodecyl sulfate, 50μM phenyl methyl sul-
fonyl fluoride, and 1μg/ml leupeptin (pH = 7.2) containing
a protease inhibitor (Complete Mini, Roche; Indianapolis, IN)
and phosphatase inhibitor cocktail (Sigma). Samples were then
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subjected to low-speed centrifugation (2000 g). Protein deter-
minations were performed using the Bio-Rad DC protein assay
(Bio-Rad; Hercules, CA). Samples (30μg total protein) were sub-
jected to a sodium dodecyl sulfate-polyacrylamide gradient gel
(4–12% Bis-Tris or 3–8% Tris-Acetate Invitrogen; Carlsbad, CA)
electrophoresis, transferred via standard apparatus (Bio-Rad) to
nitrocellulose membrane. Depending upon the study, the total
protein content of DAT, D2Rs, SERT, and 5-HT1BRs were deter-
mined by immunoprobing using the following rabbit polyclonal
antibodies: anti-D2R (1:333–1:500, Novus Biologicals), anti-
DAT (1:333–1:1:500, Millipore), anti-SERT (1:500, Millipore),
anti-5HT1BR (1:250–1:500; Lifespan Biosciences). Anti-Calnexin
(1:1000, Millipore) was used to control for protein loading and
to normalize the expression of the protein of interest. Immuno-
labeled proteins were detected using horseradish peroxidase-
conjugated secondary IgGs (diluted 1:20,000–1:80,000) (Jackson
Immuno Research) and visualized with enhanced chemilumi-
nescence (Amersham Life Sciences). Immunoreactive levels were
quantified by integrating band density × area using computer-
assisted densitometry (NIH ImageJ version 1.60). The density ×
area measurements were averaged over 3–4 control samples for
each gel and all bands were expressed as percent of the con-
trol values (SAL-1 day withdrawal for the repeated MA study;
SAL-F2B6D2 mice for the genetic study). The immunoblotting
data were analyzed using ANOVAs, followed by analyses for main
effects and t-tests for post-hoc comparisons, when appropriate.
MA-INDUCED PLACE-CONDITIONING
Groups of B6 mice were implanted with guide cannulae above the
mPFC or NAC and then subjected to a MA place-conditioning
regimen that was similar to that employed previously for stim-
ulants in our laboratory (Ary et al., 2013). The study proceeded
in five sequential phases: habituation, pre-conditioning test (Pre-
Test), MA/SAL conditioning, post-conditioning test (Post-Test),
and microinjection test (Microinjection Test). All sessions were
15min in duration and animals received no systemic injections
during the habituation, Pre-Test, Post-Test orMicroinjection Test,
when they had free-access to both compartments of the appara-
tus. For conditioning, mice received 4 alternating pairings of dis-
tinct compartments with either MA (2mg/kg; vol = 0.01ml/kg)
or an equivalent volume of saline in an unbiased fashion. One
compartment had black and white marble-patterned walls, with a
textured floor, while the other compartment had wood-patterned
walls, with a smooth Plexiglas floor. The difference in the time
spent in the drug-paired vs. unpaired compartment (CPP Score)
on the Post-Test served to index place-conditioning prior to any
intracranial manipulation. Having established that MA elicited
a conditioned place-preference (CPP), mice were assigned to
receive an intracranial infusion (0.5μl/side) of 100 nM GBR-
12909, 100 nM of the D2/3R agonist quinpirole or an aCSF vehi-
cle. The doses of GBR-12909 and quinpirole were selected to be
maximally effective for raising and lowering, respectively, extra-
cellular dopamine in on-going microdialysis studies in our labo-
ratory. Microinfusions were delivered at a rate of 0.5 ul/min via
33-gauge stainless steel tubing (12mm in length). Microinjectors
were left in place for an additional 1min prior to careful removal.
Five min later, mice were placed into the place-conditioning
apparatus for 15min. Following testing, microinjector place-
ments within the mPFC or NAC were verified in Nissl-stained
coronal tissue sections (Figure 5). The data were analyzed using
ANOVAs.
RESULTS
DA SENSITIZATION IN MA-TREATED B6 MICE
We characterized the short- and longer-term effects of a his-
tory of subchronic MA upon MA-induced DA release within
NAC and mPFC in B6 mice. As illustrated in Figure 1, acute
MA (2mg/kg) elicited a rise in extracellular dopamine that
exhibited a clear sensitization in MA-treated animals (Figure 1;
compare open vs. closed symbols in each panel) [for NAC,
Repeated Treatment × Time: F(11, 297) = 4.40, p < 0.0001; for
mPFC: Repeated Treatment × Time: F(11, 319) = 2.06, p = 0.02].
Although the magnitude and time-courses of this effect var-
ied between regions, repeated MA sensitized DA release in both
regions in a time-independent fashion as indicated by no main
or interaction effects of the Withdrawal factor for either region
(p’s> 0.20).
BASAL DA CONTENT IN MA-TREATED B6 MICE
When obtained by conventional microdialysis, the average basal
DAEC levels within both the NAC and mPFC were moder-
ately lower in MA-treated mice at 21 days withdrawal (Table 1).
However, statistical analyses of the data failed to identify any
significant main or interaction effects (all p’s > 0.06). As the
results from conventional microdialysis procedures are subject
to differences in probe recovery, we then employed quanti-
tative microdialysis procedures to examine the data for MA-
induced changes in basal DAEC and DA clearance from the
probe. Using no net-flux procedures and linear regression anal-
yses (Figures 2A,D), we observed time-dependent changes in
basal DAEC content (y = 0) in MA-sensitized mice within both
the NAC (Figure 2B) [Treatment × Withdrawal: F(1, 29) = 4.162,
p = 0.05] and the mPFC (Figure 2E) [Treatment × Withdrawal:
F(1, 21) = 4.767, p = 0.04]. SAL-MA differences in y = 0 were
not present in either region at 1 day withdrawal (t-tests, p’s >
0.05), but group differences were apparent at 21 days withdrawal
[for NAC, t(11) = 3.08, p = 0.01; for mPFC, t(11) = 3.13, p =
0.01]. The MA-induced reduction in DAEC content was unre-
lated to changes in release/reuptake, as group differences were
Table 1 | When assayed using conventional in vivo microdialysis
procedures, we failed to detect an effect of repeated
methamphetamine experience or withdrawal upon basal
extracellular dopamine (fg/20μl dialysate) within either the mPFC or
the NAC.
Saline Methamphetamine
1 day WD 21 days WD 1 day WD 21 days WD
mPFC 0.55 ± 0.13 (8) 0.78 ± 0.16 (7) 0.95 ± 0.25 (9) 0.59 ± 0.16 (9)
NAC 3.60 ± 0.74 (7) 3.78 ± 0.92 (7) 3.03 ± 1.22 (8) 1.00 ± 0.24 (8)
The data represent the mean ± s.e.m. of the number of animals indicated in
parentheses.
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FIGURE 2 | Summary of the results of a dopamine no net-flux in vivo
microdialysis study conducted at either 1 or 21 days withdrawal (WD) in
B6 mice with a 10-day history of repeated methamphetamine (2mg/kg;
MA) or saline (SAL) within the NAC core-shell interface (A–C) and the
mPFC (D–F). Linear regression analyses (A,D) conducted on the plots of the
net flux of dopamine vs. the amount of dopamine infused revealed
time-dependent changes in y = 0 (B,E), an estimate of basal extracellular
dopamine content, in MA-sensitized mice within both the NAC and the
mPFC. (C,F) There were no group differences in the slopes/extraction
fractions (Ed) of the linear regressions. The data represent the means ±
s.e.m’s of the number of animals indicated in parentheses in each panel.
∗p < 0.05 vs. SAL; +p < 0.05 vs. 1-day WD.
not observed regarding Ed derived from the slopes of the linear
regressions for either region (Figures 2C,F) [for NAC, Treatment
effect: F(1, 29) = 7.48, p = 0.01; no Withdrawal main or inter-
action effect, p’s > 0.15; for mPFC, Treatment: F(1, 21) = 4.81,
p = 0.04; Withdrawal: F(1, 21) = 15.831, p = 0.001; interaction:
p = 0.27].
DAT EXPRESSION AND FUNCTION IN MA-TREATED B6 MICE
We next related MA-induced changes in DAEC to the expression
and function of DAT using microdialysis and immunoblotting
approaches. MA withdrawal did not affect the capacity of GBR-
12909 to elevate DAEC levels within either the NAC (Figure 3A) or
themPFC (Figure 3C) (for both regions, Dose effects: p’s< 0.001;
no main or interaction effect of the Repeated Treatment factor:
p’s > 0.05). MA treatment also did not alter DAT expression
within the NAC shell (not shown) or mPFC (Figure 3D; Two-
Way ANOVA’s, p’s > 0.05). However, drug treatment reduced
DAT expression within the NAC core (Figure 3B), although the
results did not support a time-dependency to this effect [Repeated
Treatment effect: F(1, 39) = 4.26, p = 0.05; no Withdrawal effect
or interaction, p > 0.20].
D2R EXPRESSION AND FUNCTION IN MA-TREATED B6 MICE
We then related MA-induced changes in DAEC to the expression
and function of D2/3Rs using microdialysis and immunoblotting
approaches. MA withdrawal blunted D2/3R function within the
NAC at both withdrawal time-points (Figure 4A) [1 day: Dose ×
Repeated Treatment: F(1, 14) = 11.18, p = 0.005; t-tests; 21 days:
effects of Dose and Treatment: p’s < 0.006, but no interaction:
p = 0.27]. MA animals also exhibited reduced receptor expres-
sion at the 21-day withdrawal time-point within the NAC core
(Figure 4B) [Repeated Treatment × Withdrawal (α = 0.1 based
on microdialysis results): F(1, 38) = 3.739, p = 0.06; post-hoc, 1
day WD, Repeated Treatment: p = 0.68; 21 days WD, F(1, 18) =
5.378, p = 0.03]. No change in D2R expression was observed
within the NAC shell (Two-Way ANOVAs, α = 0.1, all p’s >
0.25). While MA history did not impact the sulpiride-induced
rise in DA within the mPFC at 1-day withdrawal [Dose effect:
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FIGURE 3 | Summary of the effects of a 10-day history of repeated
methamphetamine (MA; 2mg/kg) or saline (SAL) upon the capacity of
the DAT reuptake inhibitor GBR-12909 to elevate extracellular dopamine
(A,C) and upon total DAT protein expression (B,D) within the NAC (top
panels) and mPFC (bottom panels) at 1 and 21 days withdrawal (WD).
The data are presented as the percent change from the average baseline
level of neurotransmitter and represent the means ± s.e.m’s of the number
of animals indicated in parentheses in each panel.
F(1, 13) = 19.12, p < 0.001; no main or interaction effect of the
Repeated Treatment factor, p’s > 0.10], MA reduced responsive-
ness to the 100μM dose in the long-term (Figure 4C) [Dose ×
Repeated Treatment: F(1, 14) = 8.56, p = 0.01; t-tests: p’s< 0.05].
However, we failed to detect changes in D2R expression within the
mPFC (Figure 4D; Two-Way ANOVA’s, all p’s> 0.05).
MA-INDUCED CPP IN B6 MICE
The data presented above indicated that subchronic MA expo-
sure was sufficient to produce enduring anomalies in DAEC
within both the mPFC and NAC. As the role for DAEC
in mediating MA preference has not been fully vetted, we
examined the effects of raising (via site-directed infusions of
the DAT inhibitor GBR-12909) or lowering (via site-directed
infusions of the D2/3 autoreceptor agonist quinpirole) DAEC
upon the expression of a MA-conditioned place-preference.
Neuropharmacological manipulation of the NAC impacted the
expression of a MA-induced place-conditioning in B6 mice
(Figure 5A) [Side × Test × Drug: F(2, 21) = 18.60, p < 0.0001].
In the absence of intra-NAC infusion (Post-test), there were
no group differences in CPP magnitude (Side × Treatment,
p > 0.50). However, group differences emerged with respect
to both the extent and direction of place-conditioning upon
intra-NAC microinjection [Side × Treatment: F(2, 21) = 48.49,
p < 0.0001]. Vehicle-infused animals exhibited a non-significant
CPP [Side effect: p = 0.11], GBR12909 facilitated CPP expres-
sion [Side effect: F(1, 8) = 49.00, p < 0.0001] and quinpirole
elicited a marked conditioned place-aversion (CPA) [Side effect:
F(1, 7) = 48.52, p < 0.0001]. An analysis of CPP scores for the
Microinjection Test confirmed greater CPP in GBR12909-infused
animals vs. vehicle controls [F(2, 21) = 48.49, p < 0.0001; t-tests,
p’s < 0.05]. In contrast, intra-mPFC DA manipulations failed to
alter CPP expression across 2 replicates of study (Figure 5B) [Side
effect: F(1, 39) = 32.72, p < 0.0001; Test effect: F(1, 39) = 11.85,
p < 0.0001; no main or interaction effect of the Drug factor,
p’s> 0.30].
MONOAMINE CONTENT IN MAH/LDR MICE
The data for MA-injected B6 mice indicate that a history
of subchronic MA exposure is sufficient to produce endur-
ing alterations in basal DAEC within both the NAC and
mPFC (Figure 2). Moreover, the neuropharmacological results
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FIGURE 4 | Summary of the effects of a 10-day history of repeated
methamphetamine (MA; 2mg/kg) or saline (SAL) upon the capacity of
the D2/D3 receptor antagonist sulpiride to elevate extracellular dopamine
(A,C) and upon total D2 receptor protein expression (B,D) within the NAC
(top panels) and mPFC (bottom panels) at 1 and 21 days withdrawal
(WD). The data are presented as a percent change from the average baseline
dopamine levels and represent the means ± s.e.m’s of the number of animals
indicated in parentheses in each panel. ∗p < 0.05 vs. respective SAL.
supported an important role for DAEC, particularly within the
NAC, in mediating MA-conditioned preference and aversion
(Figure 5). Thus, we determined whether or not the divergent
behavioral phenotypes of MAH/LDR mice might relate to differ-
ences in basal DAEC content. We also examined for differences in
basal 5HTECcontent, as a prior examination for biochemical cor-
relates of genetic vulnerability to highMA intake indicated higher
expression of the mRNA encoding the serotonin transporter
SERT within the NAC of MAHDR vs. MALDR mice (Wheeler
et al., 2009). Using no net-flux approaches, MAHDR-MALDR
differences were noted for NAC basal DAEC content (Figure 6A)
[t(15) = 2.50, p = 0.02], with levels being lower in MAHDR vs.
MALDR mice. mPFC DAEC content also varied with genotype
(Figure 6B) [t(15) = 2.41, p = 0.03] and again, MAHDR ani-
mals exhibited lower DA content. While no genotypic differences
were noted for mPFC 5HTEC content (Figure 6D; t-test, p =
0.92), NAC 5HTEC content varied with genotype (Figure 6C)
[t(14) = 2.89, p = 0.01], with MAHDR mice exhibiting higher
serotonin levels than MALDR animals. No genotypic differences
were observed for the Ed for either DA or 5HT within either brain
region (Table 2; One-Way ANOVA’s, all p’s > 0.35). Thus, the
genotypic differences in extracellular neurotransmitter content
were not obviously related to neurotransmitter clearance/release.
MA-STIMULATED MONOAMINE RELEASE IN MAH/LDR MICE
The results of the quantitative microdialysis studies indicated line
differences for basal DAEC and 5HTEC content (Figure 6). Thus,
we examined also for line differences in the capacity of an acute
MA injection (2mg/kg) to elevate DA and 5HT levels within the
NAC and mPFC. A summary of the average baseline levels of
DA and 5HT within the NAC and mPFC is provided in Table 3.
As the absolute amount of neurotransmitter detected by conven-
tional microdialysis procedures is subject to influences by indi-
vidual probe recovery (Westerink and Cremers, 2007), the results
obtained under conventional microdialysis procedures did not
match exactly those obtained under quantitative microdialysis
procedures. Notably, our conventional microdialysis procedures
did not detect line differences in basal NAC neurotransmitter
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FIGURE 5 | Summary of changes in the difference in the time spent (in sec)
in an environment previously paired with 2mg/kg methamphetamine
(Paired) vs. an environment paired previously with saline (Unpaired) (i.e.,
CPP Score) produced by intra-NAC (A) or intra-mPFC (B) infusions of
100nM of the DAT reuptake inhibitor GBR-12909 (GBR) or 100nM of the
D2/3 receptor agonist quinpirole (QNP). The data represent the means ±
s.e.m’s of the number of animals indicated in parentheses in each panel.
∗denotes p < 0.05 Paired vs. Unpaired; +p < 0.05 vs. respective VEH.
levels (t-tests, p’s > 0.10). However, we did detect lower DAEC
and higher 5HTEC within themPFC ofMAHDR vs.MALDRmice
[for DA, t(14) = 2.18, p = 0.04; for 5HT, t(14) = 3.63, p = 0.003].
Surprisingly, no line differences were observed for MA-
stimulated DA release within the NAC (Figure 7A) [Time effect:
F(11, 154) = 5.09, p < 0.0001; interaction: p = 0.85]. In contrast,
marked differences were observed for MA-induced DA release
in the mPFC (Figure 7B) [Genotype × Time: F(22, 154) = 3.12,
p = 0.001]. As illustrated in Figure 7B, 2mg/kg MA injection
produced a robust (2–3-fold increase) in mPFC DA levels in
MAHDR mice [F(11, 66) = 2.33, p = 0.02]. In contrast, the MA
injection did not elevate mPFC DA levels at all in MALDR mice;
rather, their DA levels dropped below baseline post-injection
[F(11, 88) = 4.82, p < 0.0001]. Acute MA failed to alter 5HT lev-
els in the NAC of either genotype (Figure 7C; Two-Way ANOVA,
all p’s> 0.05). However, there was an overall genotypic difference
for MA-induced increases in mPFC 5HT (Figure 7D) [Genotype
effect: F(1, 14) = 5.49, p = 0.03; no main or interaction effects
of Time: p’s > 0.20], with MALDR mice exhibiting a 2 to 2.5-
fold elevation in mPFC 5HT levels post-injection that persisted
throughout the microdialysis session and MAHDR mice exhibit-
ing no sign of MA-induced 5HT release (Figure 7D).
IMMUNOBLOTTING IN MAH/LDR MICE
Given genotype differences in basal and MA-stimulated
neurotransmitter release (Figures 6, 7), we next employed
immunoblotting to index the expression of DAT, SERT, D2R,
and 5HT1BR in the selected lines (Figure 8). The results of
the statistical analyses for all proteins failed to indicate any
main or interaction effects of the Treatment factor (all p’s >
0.05). Thus, the data were collapsed across treatments for clarity
of presentation. In the NAC shell (Figure 8A), we observed
genotypic differences in D2R [Genotype effect: F(1, 37) = 10.63,
p = 0.003], DAT [Genotype effect: F(1, 37) = 13.53, p = 0.001]
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FIGURE 6 | Summary of the results of a dopamine (A,B) and serotonin
(C,D) no net-flux in vivo microdialysis study conducted within the NAC
core-shell interface (left) and mPFC (right) in MA-naïve mice on a
genetically heterogeneous B6 × D2 background (F2B6D2) and mice
selectively bred for high vs. low MA intake (MAHDR and MALDR,
respectively). The data represent the means ± s.e.m’s of the number of
animals indicated in parentheses in each panel. ∗p < 0.05 vs. MALDR.
Table 2 | In vivo extraction fractions (Ed ) for dopamine and serotonin
in the medial prefrontal cortex (mPFC) and the nucleus accumbens
core-shell interface (NAC) of mice selectively bred for high vs. low
methamphetamine drinking (respectively, MAHDR, and MALDR), as
determined using quantitative microdialysis approaches.
MAHDR MALDR
NAC dopamine 0.96±0.03(8) 0.89±0.07(9)
NAC serotonin 1.00±0.15(7) 1.05±0.09(9)
mPFC dopamine 0.85±0.14(8) 0.84±0.07(11)
mPFC serotonin 1.41±0.23(8) 1.49±0.22(11)
The data represent the mean ± s.e.m. of the number of animals indicated in
parentheses.
and SERT [Genotype effect: F(1, 37) = 4.90, p = 0.03] expres-
sion, with MAHDR mice exhibiting lower D2R levels, but higher
transporter levels, vs. MALDR animals. Genotypic differences
were not observed for NAC shell 5HT1BR expression. In contrast
MAHDR mice exhibited higher DAT and SERT levels relative
to MALDRalso varied with genotype within the NAC shell, but
this effect did not reach statistical significance [Genotype effect:
p = 0.06]. SERT levels varied significantly with genotype in
the NAC shell [Genotype effect: F(2, 57) = 4.79, p = 0.01], with
MAHDR mice exhibiting higher expression vs. the other geno-
types (LSD post-hoc tests, p’s < 0.02). No genotypic difference
in 5HT1BR was observed in the NAC shell (Genotype effect,
p > 0.35). In the NAC core (Figure 8B), MAHDRmice exhibited
Table 3 | Basal extracellular levels of dopamine and serotonin (in
fg/27µl sample) within the medial prefrontal cortex (mPFC) and the
nucleus accumbens (NAC) of mice selectively bred for high vs. low
methamphetamine drinking (MAHDR and MALDR, respectively), as
determined using conventional microdialysis approaches.
MAHDR MALDR
NAC dopamine 8.75±1.13(8) 7.82± 1.26(9)
NAC serotonin 3.99±0.74(9) 3.42± 0.59(7)
mPFC dopamine 1.38±0.33*(7) 2.78± 0.64(9)
mPFC serotonin 6.96±0.80*(7) 3.32± 0.66(9)
The data represent the mean ± s.e.m. of 3 dialysate samples, collected dur-
ing the hour prior to a methamphetamine injection. The number of animals
employed in the statistical analyses of the data is indicated in parentheses.
*p < 0.05 (t-test).
FIGURE 7 | Summary of the change in extracellular dopamine (A,B)
and serotonin (C,D) exhibited within the NAC core-shell interface (left)
and mPFC (right) of genetically heterogeneous B6 × D2 mice (F2B6D2)
and mice selectively bred for high vs. low MA intake (MAHDR and
MALDR, respectively) administered an acute injection of 2mg/kg MA.
The data are expressed as a percent change from the average baseline
values and represent the means ± s.e.m’s of the number of animals
indicated in parentheses in each panel. ∗p < 0.05 vs. average baseline.
lower 5HT1BR expression but higher DAT expression than
MALDR animals [for 5HT1BR, Genotype effect: F(1, 38) = 6.13,
p = 0.02; for DAT, Genotype effect: F(1, 38) = 5.46, p = 0.03].
Genotypic differences were not noted for D2R or for SERT
expression within the NAC core (Genotype effects, p’s > 0.10).
In the mPFC (Figure 8C), we observed no line differences for the
D2R (Genotype effect: p = 0.29). Overall, MAHDR exhibited
higher 5HT1B levels than MALDR mice, but this difference
was shy of statistical significance (Genotype effect: p = 0.07).
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FIGURE 8 | Comparison of protein expression within the nucleus
accumbens shell (NACs) (A), the nucleus accumbens core (NACc) (B)
and the medial prefrontal cortex (mPFC) (C) for the D2 dopamine
receptor, the dopamine transporter (DAT), the 5HT1B receptor and the
serotonin transporter (SERT) of genetically heterogeneous B6 × D2 mice
(F2B6D2) and mice selectively bred for high vs. low MA intake (MAHDR
and MALDR, respectively). As the results of the statistical analyses of the
data for all proteins failed to indicate an effect of the MA challenge injection
upon protein expression, the data were collapsed across injection groups for
clarity of presentation of genotypic differences. The data represent the
means ± s.e.m’s of the number of animals indicated in parentheses in each
panel. ∗p < 0.05 vs. MALDR.
and the rise in 5HT1BR expression observed in MAHDR. there
was a moderate genotypic difference in 5HT1BRs that reflected
lower levels in both selected lines, compared to F2B6D2 mice
[Genotype effect: F(2, 59) = 2.99, p = 0.06]. A similar pattern
of genotypic differences were observed for the D2 receptor
[Genotype effect: F(2, 59) = 4.68, p = 0.01], with F2B6D2 mice
exhibiting significantly higher receptor levels, compared to both
selected lines (LSD post-hoc tests, p’s < 0.05). We could not
detect DAT within the mPFC of the mice in this study, and no
differences were noted for SERT expression (Genotype effect:
p > 0.45).
DISCUSSION
An understanding of the neurobiological substrates of MA addic-
tion vulnerability and the effects of subchronic, subtoxic, MA
experience upon the brain is critical to understanding the etiology
of MA addiction, identifying potential biomarkers for MA addic-
tion vulnerability/resiliency and developing treatment strategies
for early intervention in the disease process. The present stud-
ies were conducted to further extend knowledge regarding the
interactions between subchronic MA exposure and forebrain DA
and to relate anomalies in forebrain DA and 5HT to genetic
vulnerability/resiliency to high MA intake.
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SUBCHRONIC MA ELICITS A TIME-INDEPENDENT SENSITIZATION OF
CORTICOLIMBIC DA
Regional differences existed in MA’s ability to elicit DA release
within the 2 major terminal regions of the mesocorticolimbic
DA system and regional differences were apparent with respect
to the time-course of DA release in both acute and repeated
MA-treated animals (Figure 1). As reported previously (Shoblock
et al., 2003), MA elicited a markedly larger rise in DAEC within
the NAC than within the mPFC, although the MA-induced ele-
vation in DAEC produced within the mPFC was more persistent
than that observed within the NAC. This regional distinction in
the DA response to MA might relate to regional differences in
DAT expression, which is higher in striatal vs. frontal cortical
structures (Sesack et al., 1998). Higher DAT expression within
the NAC could account for the larger magnitude of MA effect
and the faster rate of decline in DAEC observed in the NAC,
relative to the mPFC. Regional differences exist also in the rela-
tive roles played by metabolizing enzymes, monoamine oxidase
(MAOs) and catechol-O-methyltransferase (COMT), in deter-
mining DAEC (e.g., Karoum et al., 1994). MAO can be inhibited
by MA (e.g., Fleckenstein et al., 2007; Chen et al., 2009) and by
virtue of the fact that the majority of DA released within striatal
structures is removed into neuron terminals by DAT (Sesack et al.,
1998), MAOs play a more critical role in regulating DAEC within
striatum than they do within frontal cortex, where DAT expres-
sion is relatively low (Karoum et al., 1994). However, the fact that
theMA-induced rise in DAEC was less persistent within NAC than
withinmPFC (Figure 1), argues less in favor of a role forMA inhi-
bition of MAO as a major contributing factor to the rise in NAC
DA observed in acute MA-injected animals.
Regardless of regional differences in the time-course of MA-
stimulated DA release, a subchronic history of MA was sufficient
to elicit DA sensitization within both the NAC and the mPFC of
male B6 mice. It is notable that in both the cases of the NAC
and the mPFC, two features of the time-course of MA-induced
DA release varied as a function of MA experience: the magni-
tude of the initial rise and the persistence of the rise, particularly
during the last hour post-injection. Markedly apparent for both
regions, MA-experienced animals exhibited a higher initial rise in
DAEC post-injection than did animals acutely administered drug.
Such findings suggest the repeated MA experience may increase
the amount or function of plasma membrane or vesicular trans-
porters or in the availability of vesicular DA for release. While
we did not assay for changes in the levels of the vesicular trans-
porter, we did not detect any obvious relation between sensitized
DA release and the protein levels of DAT within either the NAC
or mPFC. Moreover, we failed to detect SAL-MA differences in
the rise in DAEC produced by infusion of GBR-12909, which
depends upon both the availability of DAT for binding and the
integrity of impulse-dependent DA release mechanisms. Thus,
at the present time, it would not appear that alterations in DAT
function/expression or in mechanisms regulating the releasability
of DA contribute significantly to the sensitization of the ini-
tial rise in DAEC observed in MA-experienced mice, although
these mechansims were cannot be vetted thoroughly using in vivo
microdialysis and conventional immunoblotting methods. The
fact that the rise in DAEC elicited by the MA challenge injection
was more persistent in MA-experienced vs. acutely treated ani-
mals (Figure 1) suggests that perhaps repeated drug experience
lowered DA catabolism. As mentioned above, MA inhibits MAO
(Fleckenstein et al., 2007) and the possibility exists that with
repeated drug experience, this mechanism may contribute to this
drug’s capacity to promote higher DAEC levels, particularly within
the NAC (Popova et al., 2004). In contrast to striatum, frontal cor-
tical structures exhibit low DAT expression (Sesack et al., 1998).
As such, DAT and MAOs play less of a role in DA catabolism
within frontal cortex than they do within subcortical regions (e.g.,
Karoum et al., 1994) and DA catabolism is mediated in large part
by COMT, particularly under conditions of elevated DAEC such
as those produced by MA treatment (e.g., Karoum et al., 1994;
Huotari et al., 2002a,b; Matsumoto et al., 2003). While specula-
tive at this time, the possibility exists that repeated MA treatment
reduces also the function of COMT, via some indirect mecha-
nism, that may promote the amount of DAEC. Given the reliance
of mPFC DAEC upon COMT, this mechanism would be predicted
to impact the duration of the DA response to MA more so in this
region than within NAC. However, arguing against a major role
for drug-induced deficits in COMT in mediating the sensitization
of MA-induced DA release is evidence that neither pharmacolog-
ical inhibition of COMT nor null COMT mutation significantly
impact amphetamine-induced increases in DAEC within striatum
or frontal cortex (Törnwall and Männistö, 1993; Törnwall et al.,
1993; Tuomainen et al., 1996; Gogos et al., 1998; Männistö and
Kaakkola, 1999; Huotari et al., 2002a,b).
Irrespective of the mechanisms at play, the fact that sub-
chronic dosing with subtoxic MA elicited sensitization within
both the NAC and mPFC is a finding in line with ear-
lier reports for MA-experienced rodents (e.g., Stephans and
Yamamoto, 1995; Zhang et al., 2001; Broom and Yamamoto,
2005; Lominac et al., 2012; Lac´an et al., 2013; Le Cozannet
et al., 2013; but see Ago et al., 2006, 2007, 2012). Moreover,
the DA sensitization was time-independent, manifesting at 1 day
post-treatment and persisting, unchanged, for at least 21 days
(Figure 1). This finding distinguishes MA-induced DA sensitiza-
tion from that produced by repeated cocaine or amphetamine,
the latter two of which tends to grow with the passage of
time during withdrawal (e.g., Paulson and Robinson, 1995;
Vanderschuren and Kalivas, 2000). Nevertheless, the present
results for MA-injected B6 mice are qualitatively similar to results
from relatively recent studies, in which rats with a history of
behavior-contingent vs. non-contingent intravenous MA expo-
sure displayed MA-induced DA sensitization that manifested
early in withdrawal (Lominac et al., 2012; Lac´an et al., 2013;
Le Cozannet et al., 2013). While requiring further study, par-
ticularly with respect to MA pharmacokinetics (see Segal and
Kuczenski, 2006 for Discussion), the capacity of repeated MA
to elicit time-independent DA sensitization within the NAC
(and perhaps also within the mPFC) is qualitatively similar
across rodent species, routes of delivery and contingency of
delivery, which renders non-contingent models of MA admin-
istration well-suited for the study of the psychobiological con-
sequences of subchronic MA exposure of relevance to MA
abuse and the development of addiction (see also Lac´an et al.,
2013).
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Peculiarly, the expression of MA-sensitized DA release within
neither the NAC nor the mPFC of male B6 mice was not obvi-
ously related to drug effects upon basal DAEC (Table 4). First,
changes in DAEC were only apparent in the long-term (Figure 2),
while DA sensitization was manifest in early withdrawal. Second,
MA history oppositely affected DAEC in the mPFC (increase) and
NAC (decrease), despite eliciting DA sensitization within both
regions (Table 4). DA transmission within the NAC is highly
implicated in mediating the incentive motivational properties of
drugs and conditioned stimuli, as well as those for natural rein-
forcers, (e.g., Berridge and Robinson, 1998; Di Chiara, 1999;
Robinson and Berridge, 2008; Wise, 2008; Blum et al., 2012).
Indeed, the data from our neuropharmacological study of the
NAC supports a bi-directional role for NAC DA in regulating
the motivational valence of MA-conditioned environments, with
elevated DA promoting the expression of conditioned approach
and reduced DA eliciting conditioned avoidance (Figure 5A). In
contrast, neuropharmacological manipulations of mPFC DA did
not impact the magnitude or direction of conditioned behavior
in our place-conditioning paradigm (Figure 5B). Such findings
indicate that mPFC DAEC, particularly that within the prelim-
bic cortex (see histology in Figure 5B), does not actively regulate
the recall of a drug-context associations or the conditioned incen-
tive motivational properties of a drug-paired environment. This
contrasts with the role for mPFC DA role in the acquisition of
place-conditioning reported previously (e.g., Wilkinson et al.,
1998; Hayen et al., 2014). The divergent effects of subchronic
dosing with MA upon basal DAEC within the NAC and mPFC
indicate that distinct cellular or molecular mechanism(s) under-
pin the changes in basal vs. stimulated DA release in suchronic
MA-treated animals within corticolimbic DA terminals.Whatever
these mechanism(s) are that operate within the NAC and mPFC
to impact DAEC in the drugged vs. undrugged state (see below),
their dysregulation by a suchronic history of MA injections is
regionally selective and temporally distinct.
NAC DA, MA PREFERENCE AND GENETIC VULNERABILITY TO MA
INTAKE
High-dose MA injection regimens are well-characterized to
induce neurotoxicity within DA neurons in dorsal striatum,
while sparing DA neurons within the NAC (c.f., Carvalho et al.,
2012). However, evidence from studies using more moderate MA
treatment regimens, including that herein (Figure 2B), indicate
that subchronic, subtoxic MA can also lower NAC basal DAEC.
The reduction in NAC basal DAEC observed in male B6 mice
herein is akin to that reported previously in male rats subjected to
an identical MA injection regimen as that employed in the present
study (Broom and Yamamoto, 2005). However, in contrast to this
earlier study of rat, reduced basal DAEC was apparent in our male
mice only in protracted withdrawal and was paralleled by reduced
DAT expression, but no discernable change in DAT function (as
assessed by either Ed or the DA response to GBR-12909 infusion)
(Table 4). Reduced striatal DAT binding is observed consistently
in imaging studies of human MA addicts and MA-experienced
non-human primates, even during protracted withdrawal (e.g.,
McCann et al., 1998; Sekine et al., 2001, 2003; Volkow et al.,
2001a,b; Johanson et al., 2006; Groman et al., 2012). However, in
MA-injected rats, reduced NAC basal DAEC was reported to co-
occur with increased DAT function and expression (Broom and
Yamamoto, 2005). As this prior rat study did not examine for
long-term changes in NACDA levels or DAT expression/function,
it is not known if MA-induced changes in DAT expression within
the rat is biphasic with respect to time in withdrawal or if species
differences exist for the long-term effects of repeated MA expo-
sure upon NACDA.Moreover, we and others have failed to detect
pronounced changes in indices of NAC basal DA in rats with his-
tories of intravenous MA (Schwendt et al., 2009; Lominac et al.,
2012; Lac´an et al., 2013; Le Cozannet et al., 2013). Thus, the role
played by route of administration in the manifestation of MA-
induced anomalies in DAEC and DAT requires more systematic
preclinical investigation.
In contrast to a recent study in non-human primates which
failed to detect changes in D2R levels within the more ventral
aspects of the striatum in MA-experienced subjects (Groman
et al., 2012), our MA treatment regimen administered to male
B6 mice reduced NAC D2R expression in long-term withdrawal
(Figure 4). It is interesting to note that while this change in
protein expression was late to manifest, an impairment in NAC
D2/3R function was apparent very early in withdrawal prior to
detectable changes in protein levels (Figure 4). Such data indi-
cate a cause-effect relation between subchronic MA exposure and
functional anomalies in D2/3Rs that are not necessarily related to
gross alterations in total D2R protein expression, but could reflect
changes in D3Rs, the latter of which we could not reliably detect
Table 4 | Comparison of the dopamine effects of subchronic, subtoxic methamphetamine (MA) vs. saline (SAL) treatment and the dopamine
phenotype of MA-naïve MAHDR vs. MALDR mice.
NAC mPFC
MA- vs. SAL- treated MAHDR vs. MALDR MA- vs. SAL-treated MAHDR vs. MALDR
Basal extracellular content ↓ (protracted WD) ↓ ↑ (protracted WD) ↓
MA-elicited dopamine release ↑ — ↑ ↑
Total DAT protein ↓ (core) ↑ (shell and core) — n.d.
DAT function — n.d. — n.d.
Total D2 receptor protein ↓ (core) ↓ (shell) — —
D2/3 receptor function ↓ n.d. ↓ (protracted WD) n.d.
WD, withdrawal. ↑ denotes relative increase; ↓ denotes relative decrease;—denotes no change; n.d., denotes not determined.
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with our immunoblotting procedures. Alternatively, as we mea-
sured total protein expression, the possibility existed that drug-
elicited changes in the surface expression of proteins may have
been masked by the study of whole tissue homogenate. D2/3Rs
operate presynaptically as autoreceptors to inhibit both basal and
impulse-dependent DA release (c.f. Ford, 2014). As such, the
temporal relation between lowered D2/3R function and reduced
DAEC is not obvious at the present time. Nevertheless, these data
extend the results of non-human primate studies (e.g., Groman
et al., 2012) by demonstrating a cause-effect relation between sub-
chronicMA history and NACD2R expression/function that is not
afforded in imaging studies of humans. This demonstration is of
high clinical relevance given the purported link between polymor-
phisms in the gene encoding D2R, D2R hypofunctioning andMA
addiction vulnerability, as well as addiction severity, in human
and non-human primates (c.f., Blum et al., 2012; e.g., Lee et al.,
2009; Groman et al., 2012).
Related to this latter point, female MAHDR mice exhibited
lower NAC D2R expression, compared to their MALDR coun-
terparts and the reduced NAC D2R expression was accompa-
nied by lower basal DAEC, but higher DAT levels within this
region (Table 4). The former two observations are consistent
with the effects of subchronic MA upon the NAC of male B6
mice observed herein (Table 4) and are more, rather than less,
consistent with recent work in non-human primates correlat-
ing low basal D2R availability within striatum to subsequent
MA-taking (Groman et al., 2012). The higher DAT expression
observed in MAHDR vs. MALDR female mice is consistent with
earlier results for MA-injected male rats, which was suggested to
contribute to the low DAEC observed in MA-experienced ani-
mals (Broom and Yamamoto, 2005). Thus, drug-naïve or acute
MA-injected female mice with a genetic predisposition to con-
sume high amounts of MA exhibit DA anomalies within the
NAC that are similar to, but not identical with, those reported
in MA-experienced male rodents (Table 4). This later finding
is interesting as earlier research clearly indicates that the stria-
tum of female mice are much less sensitive to the neurotoxic
effects of high-dose MA injection regimens, compared to males
(Wagner et al., 1993; Yu and Wagner, 1994). Moreover, both
female rodents (Morissette and Di Paolo, 1993a,b; Rivest et al.,
1995; Bhatt and Dluzen, 2005; Ji and Dluzen, 2008) and humans
(Lavalaye et al., 2000; Mozley et al., 2001; Staley et al., 2001)
are reported to exhibit higher DAT expression or function than
males. As we were limited in the total number and the sex of
MAH/LDR animals available to study, it remains to be deter-
mined whether or not (1) MAHDR and MALDR mice differ in
terms of DAT or DA autoreceptor function within the NAC (or
other regions for that matter) and (2) the divergent D2R, DAT
and DAEC observed in MAH/LDR females mice occur also in
males. Moreover, we could not determine how differences in basal
DAEC, DAT, and D2R contribute to the divergent behavioral phe-
notypes of MAH/LDR mice nor could we determine the extent
to which line differences in indices of DA function interact with
sex to influence behavior. Nevertheless, from the similarities in
NAC DA exhibited by suchronic MA-treated male and geneti-
cally vulnerable female mice (see Table 4), our findings herein
resonate with results of recent studies for non-human primates
indicating that either drug-induced or idiopathic reductions in
NAC D2R expression and basal DAECmay be critical biochemi-
cal triggers and/or predictors of subsequent high MA preference
and intake (see Groman and Jentsch, 2013 for more detailed dis-
cussion). Extrapolating to the human condition, reduced striatal
D2R binding reported in MA-addicted individuals (e.g., Volkow
et al., 2001a; Lee et al., 2009) could very well reflect a combina-
tion of a pre-existing and drug-elicited hypo-DAergic state and
further preclinical research is required in order to determine how
idiopathies in ventral striatal D2R or basal DAEC predict indi-
vidual variation in MA preference and intake of relevance to the
development of an addicted state.
PFC DA AND VULNERABILITY TO MA ADDICTION
A subchronic history of subtoxic MA exposure increased mPFC
DAEC in B6 mice (Figure 2E), a finding in line with reduced
tissue DOPAC reported in rats with a history of intravenous
MA self-administration under short-access, operant procedures
(Schwendt et al., 2009). Also consistent with this prior work, the
MA-induced rise in mPFCDAEC observed herein was found to be
unrelated to indices of DAT function as we failed to detect saline-
MA differences in the Ed for mPFC DA (an index of basal DA
release/reuptake; Sam and Justice, 1996), total DAT expression or
the capacity of intra-mPFC GBR-12909 infusions to elevate DAEC
(Figures 3C,D). Such data argue that the rise in mPFC DAEC that
manifests during protracted withdrawal from subchronic MA is
not likely mediated by drug effects upon DAT and may very well
reflect drug-elicited changes in other monoamine transporters,
most notably NET. While we attempted to measure NET within
the mPFC of our MA-injected mice to begin to address this
possibility, the experiment was fraught with technical difficul-
ties related to signal reliability of the available anti-NET primary
antibodies, which prevented any firm conclusions on the matter.
Future studies should assay the functional involvement of NET via
the local infusion of selective reuptake inhibitors to probe the role
for MA-induced changes in transporter function in the regulation
of DAEC within mPFC.
Consistent with the earlier report for MA self-administering
rats (Schwendt et al., 2009), as well as rats treated non-
contingently with drug (Liu et al., 2009), our subchronic
MA injection regimen did not alter mPFC D2R expression
(Figure 4D), supporting the notion that drug-elicited changes in
frontal cortical DAT and D2R binding reported in MA addicts
(e.g., Volkow et al., 2001a,b; Sekine et al., 2003), likely require
extensive MA treatment histories in order to manifest (see Lac´an
et al., 2013 for Discussion). However, it is notable thatMA-treated
animals exhibited a reduced capacity of intra-mPFC sulpiride to
elevate DAEC and this effect manifested only in protracted with-
drawal (Figure 4C). Thus, the possibility exists that the elevated
DAEC observed in the mPFC of MA-injected mice may reflect,
at least in part, a progressive impairment in autoreceptor func-
tion within mPFC. To the best of our knowledge, these data
are the first to characterize the effects of MA experience and
withdrawal upon mPFC D2R function in vivo and we observe
a cause-effect relation. Thus, while anomalies in frontal cortex
function in MA addiction have been associated with low D2R
availability in caudate (e.g., Volkow et al., 2001a), the present
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data indicate that subchronic drug experience is sufficient to pro-
duce local changes in D2/3R function and DAEC within mPFC
(primarily prelimbic cortex) that are predicted to impact cogni-
tive control over drug-taking and –seeking early in the addiction
process. As discussed above for the NAC, D2R hypofunction-
ing is highly associated with addiction, as well as other disorders
characterized by motivational anomalies (c.f., Blum et al., 2012;
Jentsch and Pennington, 2014). Moreover, reducing D2R func-
tion in both drug-naïve humans and laboratory animals elicits
inhibitory control deficits that are akin to those observed in
the clinical condition (e.g., Lee et al., 2007, 2009; Herold, 2010;
Groman et al., 2011, 2012). Thus, while our attempt to probe
the functional relevance of MA-induced changes in mPFC DAEC
and D2Rs failed to support a critical role for the expression
of MA-conditioned approach/avoidance during early withdrawal
(Figure 5B). Preliminary work from our laboratory indicates that
the expression of MA-induced CPP in mice is highly resistant to
extinction, persisting for weeks, even in the face of daily extinc-
tion training (Cohen, Barrett and Szumlinski, unpublished data).
This raises the possibility that the impairment in mPFC D2/3R
function produced by subchronic MA experience might under-
pin a deficiency in learning to inhibit forward approach behavior
toward stimuli previously associated with MA and this possibility
will be a topic of future research in our laboratory.
While low D2R availability within striatal structures is highly
implicated in MA addiction vulnerability (c.f., Blum et al., 2012;
Groman and Jentsch, 2013), there is little data supporting baseline
D2R availability in frontal cortex with predisposition to addic-
tion. In the present study, we did not detect any obvious relation
between total D2R expression within mPFC and genetic vulner-
ability to high MA intake/preference (Figure 8C) and we were
unsuccessful in our attempts to reliably detect DAT expression
in the selected lines. Nevertheless, we did observe line differences
in both basal and MA-stimulated DAEC within the mPFC, which
may of relevance to their divergent phenotypes. Opposite to
MA-experienced B6 mice, MAHDR mice exhibited lower mPFC
basal DAEC; however, both MA-experienced and MAHDR ani-
mals exhibited amore pronounced rise inMA-inducedDA release
within mPFC than their respective controls (Table 4). As DA
release within mPFC contributes to the acquisition of Pavlovian
and instrumental associations (e.g., Wilkinson et al., 1998), line
differences in the DA responsiveness of the mPFC to acute
MA might account, at least in part, for their divergent pheno-
types when assessed inMA-induced place-preference and operant
self-administration paradigms (Wheeler et al., 2009; Shabani
et al., 2011, 2012a,b). That MAHDR mice exhibit “normal” MA-
induced DA release within the NAC and greater MA-induced DA
release within mPFC, in the face of lower basal content, suggests
that the high MA-drinking phenotype of these animals (Wheeler
et al., 2009) may reflect an attempt to supersede an allostatic state.
Indeed, drug-naïve MAHDR animals exhibit signs of anhedonia,
in that they exhibit lower instrumental responding for a palatable
sweet solution despite exhibiting greater responding for MA rein-
forcement, compared to MALDR animals (Shabani et al., 2012a).
Thus, the low baseline DAEC (c.f. Wise, 2008), low basal D2R
expression within the NAC (Blum et al., 2012), and/or dysregu-
lated DA-5HT interactions within both the NAC and mPFC (e.g.,
Shirayama and Chaki, 2006) may all contribute to this presumed
allostatic state inMAHDRmice that is theorized to underpin their
addiction vulnerable phenotype.
ANOMALIES IN FOREBRAIN 5HT ARE CORRELATES WITH HIGH
GENETIC VULNERABILITY TO MA INTAKE
While the majority of this study focused on DA, MAHDR mice
were reported to exhibit higher NAC Slc6a4 mRNA expression
than MALDR mice (Wheeler et al., 2009) and thus, we inves-
tigated also for genotype differences in indices of 5HT neuro-
transmission within the NAC andmPFC. Extending earlier results
(Wheeler et al., 2009), MAHDR mice exhibited higher SERT
expression within the NAC, but lower SERT expression within
the mPFC, relative to MALDR mice (Table 5). Interestingly, the
MAHDR-MALDR differences in SERT expression were inversely
related to genotype differences in 5HT1BR within these two
regions (Table 5). Thus, as observed for corticolimbic DA, geno-
type differences in indices of 5HT neurotransmission depended
upon the forebrain region investigated.
In the NAC, higher basal 5HTEC (Figure 6C) was coinci-
dent with higher SERT levels (Figures 8A,B) in MAHDR mice.
Although we did not assay SERT function directly due to lim-
ited animal availability, we failed to detect line differences in
the Ed for NAC 5HT using quantitative microdialysis proce-
dures (Table 2), indicating no difference in 5HT uptake within
this region (Sam and Justice, 1996). Thus, while the possibility
may still exist that SERT is functioning sub-optimally within the
NAC of MAHDR mice, a more parsimonious explanation is that
the rise in SERT expression is merely a compensatory response
to elevated 5HTEC, the latter of which results from 5HT1BR
hypo-functioning (Table 5). Indeed, MA-stimulated monoamine
release is primarily impulse-independent (e.g., Fleckenstein et al.,
2007; Chen et al., 2009). Therefore, a perturbation in termi-
nal 5HT1B autoreceptor function in MAHDR animals could
underpin their elevated basal 5HTEC levels, without necessar-
ily influencing the capacity of MA to raise 5HTEC. As acute
treatment with 2mg/kg MA failed to elevate NAC 5HTEC lev-
els in either genotype (Figure 7C), it is difficult to discern a
relation between the observed changes in 5HTEC, SERT and/or
5HT1BR expression to MA-induced 5HT release within the NAC.
Table 5 | Comparison of the protein expression of serotonin-related
proteins within the nucleus accumbens (NAC) and medial prefrontal
cortex (mPFC) of the MAHDR and MALDR selected lines.
NAC mPFC
Basal extracellular
content
MAHDR > MALDR MAHDR = MALDR
MA-elicited
serotonin release
MAHDR = MALDR MAHDR < MALDR
Total SERT protein MAHDR > MALDR (shell) MAHDR < MALDR
Total 5HT1B protein MAHDR < MALDR (core) MAHDR > MALDR (n.s.)
< denotes expression is less than; > denotes expression is greater than;
= denotes no difference. n.s. indicates a strong trend for a genotypic difference
that failed to reach statistical significance (i.e., p = 0.05–0.09).
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Nevertheless, the present data for MAH/LDR mice indicate that
higher basal 5HTEC and SERT, as well as lower 5HT1BR, expres-
sion within the NAC are correlates of high genetic vulnerability
to MA intake, preference and reinforcement (see Wheeler et al.,
2009; Shabani et al., 2011, 2012a,b) that are worthy of further
exploration.
As was observed for forebrain DA, there were marked regional
differences in the 5HT correlates of high vs. low genetic vulnera-
bility to self-administer MA (Table 5). While MAHDR-MALDR
differences were noted for NAC basal 5HTEC content, no line
differences were noted for mPFC basal 5HTEC content or Ed.
However, as observed for mPFC DAEC (Table 4) marked geno-
type differences were apparent regarding MA-stimulated 5HT
release in this region; however, in the latter case, MALDR mice
were considerably more sensitive to MA than MAHDR animals
(Figure 7D). In fact, the genotype difference in MA-induced 5HT
release within mPFC was polar opposite that observed for DA
release in this region (Figures 7B vs. 7D). This suggests a recip-
rocal interplay between these two monoamines systems, the basis
of which cannot be discerned from the results of the present study.
Nevertheless, the line differences in MA-induced 5HT release
within the mPFC was associated with significant genotype differ-
ences in SERT andmore moderate differences in 5HT1BR expres-
sion (Table 5). Notably, MAHDR mice displayed lower SERT and
higher terminal autoreceptor expression, relative to MAHDR ani-
mals. Thus, the failure of MA to elevate 5HTEC within the mPFC
of MAHDR mice might relate to their lower levels of SERT,
although the possibility that higher 5HT1BR autoreceptor tone
might influence the amount of 5HT release cannot be negated at
this time. Together, the above data for 5HT in MAH/LDR mice
implicate anomalies in both basal and MA-induced changes in
corticolimbic 5HT transmission in the propensity to develop a
MA-addicted phenotype and research into individual variation in
indices of mesocorticolimbic 5HT transmission and MA addic-
tion, as well as a more systematic characterization of the effects of
MA history upon forebrain 5HT, are warranted at both the clin-
ical and preclinical levels in order to better understand the inter-
relation between MA addiction vulnerability, addiction severity
and 5HT.
CONCLUSIONS
While a number of questions still remain, the results of the present
study indicate that a history of subchronic, subtoxic MA is suf-
ficient to produce a persistent dysregulation of indices of DA
neurotransmission within the NAC andmPFC ofmice. Moreover,
we demonstrated that DA within the NAC, but not mPFC,
actively regulates the expression of MA preference and mice with
genetic vulnerability for high MA intake exhibit DA anomalies
within the NAC, many of which are akin to those produced
by subchronic MA experience. As the MA injection regimen
employed herein attempted to model early drug experience, these
data suggest an important role for idiopathic or drug-elicited
anomalies in NAC DA for MA preference/intake. Moreover, as
mice with a genetic vulnerability to high MA intake exhibit
also anomalies in 5HT, particularly within the mPFC, impli-
cates also mPFC 5HT neurotransmission in the etiology of MA
addiction.
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